Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
Trial status:Study Complete
Study Identifier:
RB_0003-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18+
Estimated Trial Date
Mar 2015 - Jun 2023
Protocol summary
The purpose of this study is to determine the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine targeting four tumor-associated antigens in patients with advanced melanoma.
Trial locations
Location
Status
Location
Johann Wolfgang Goethe Universität Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie
Frankfurt, Germany, 60590
Status
Location
Universität Heidelberg, Dermatologie und NCT
Heidelberg, Germany, 69120
Status
Location
Universitätsmedizin Mainz, Hautklinik und Poliklinik
Mainz, Germany, 55131
Status
Location
Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie
Mannheim, Germany, 68167
Status